Today's Top Stories


Hot Topics


Comment & Analysis »

GlobalData Healthcare

PD-1s show early promise in melanoma brain metastases

One of the most frequent and terminal complications of advanced melanoma—the most aggressive form of skin cancer—is brain metastases. Melanoma brain metastases (MBM) occur in approximately...

PD-1s show early promise in melanoma brain metastases
GlobalData Healthcare

How biomarker-driven cancer immunotherapy can benefit both patients and developers

How biomarker-driven cancer immunotherapy can benefit both patients and developers
GlobalData Healthcare

Phase III failure puts the future of Alcobra in doubt

Phase III failure puts the future of Alcobra in doubt
GlobalData Healthcare

Eli Lilly aims to dominate the migraine market

Eli Lilly aims to dominate the migraine market
GlobalData Healthcare

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Company Releases »

Softigel by Procaps Brochure

Softigel
Softigel by Procaps Brochure

Using FlexyCUBE in Risk and Quality Analysis

SYSTAG Systems Technik
Using FlexyCUBE in Risk and Quality Analysis

Research Models to Evaluate Drug Candidate Efficacy

Pharmatest Services Research Models to Evaluate Drug Candidate Efficacy

Using Mophologically Directed Raman Spectroscopy to Detect Counterfeit Drugs

Malvern Instruments
Using Mophologically Directed Raman Spectroscopy to Detect Counterfeit Drugs

Custom Monoclonal and Polyclonal Antibody Development

ImmunoPrecise Antibodies Custom Monoclonal and Polyclonal Antibody Development

Drugdevelopment Insights »

Drugdevelopment Industry Reports »

Report: Lupus market to reach $3.2bn in value by 2025

Report: Lupus market to reach $3.2bn in value by 2025

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis

FDA approves first new drug for Atopic Dermatitis in over a decade

FDA approves first new drug for Atopic Dermatitis in over a decade








cachename:HomePagecachekey:rd-1665407042_1729060782_rd-488908060_1460672566_ap1460672566_1729060782_1903286115